Objective-Angiogenesis is an important biological process during development, reproduction, and in immune responses.
A ngiogenesis, the process by which new blood vessels form from pre-existing vessels, differs from vasculogenesis in that mesoderm precursor cells differentiate into new endothelial cells in angiogenesis. Vasculogenesis is the process by which the first vessels form during embryonic development. 1, 2 Placental growth factor (PlGF), a subfamily of the vascular endothelial growth factor (VEGF), is a key molecule in angiogenesis and vasculogenesis, especially during embryogenesis. VEGF binds to VEGF receptor-1, a key receptor involved in vessel formation during embryogenesis. VEGF-B and PlGF can also bind VEGF receptor-1. [3] [4] [5] PlGF has been found in the placenta, 6, 7 where it was shown to control trophoblast growth and differentiation and to exhibit high expression in placenta from women with fetal growth restriction. 8 Many tissues and organs, including the villous trophoblast and heart, express PlGF, and endothelial cells express PlGF during vascular development. [9] [10] [11] [12] [13] Moreover, the placental trophoblast is the main source of PlGF during pregnancy, and its expression is significantly upregulated at an early gestational age after implantation. 9 PlGF knockout mice do not have defects in vascular development and show normal embryogenesis. However, reduced collateral vascular growth has been observed in PlGF knockout mice under pathological conditions such as inflammation or ischemia. 14 Presently, the function of PlGF and its related signaling mechanisms remain poorly understood.
PlGF is related to survival and the angiogenesis pathway through phosphatidylinositol 3-kinase, downstream of VEGF receptor-1. 15 PlGF also significantly upregulates extracellular signal-regulated kinase (ERK)-1 and ERK-2 activity in endothelial cells. Moreover, PlGF activates ERK1/2 kinases, which are associated with cellular survival and proliferation. ERK activation in the placenta is essential to vascular development. Mice in which the gene encoding this pathway member has been deleted often show embryonic death because of abnormal development of the placenta. 16 Accordingly, it is possible that abnormal expression of PlGF during pregnancy influences trophoblast function as much as vascularity in the placental bed. 17 The purpose of this study was to determine the biological function of PlGF in placental development from fetus under increased PlGF expression in T cell.
; therefore, we generated transgenic mice that overexpress PlGF in T cells using the human CD-2 promoter ( Figure 1A ). To evaluate the transgenic founder, we performed polymerase chain reaction reactions with genomic DNA ( Figure 1B) . We examine the number of copies by Fluorescence in situ hybridization analysis. The result shows that all 3 lines have 5 to 8 copies. And all 3 lines are shown similar phenotype of placenta and embryo development (data not shown). Moreover, we isolated mRNA from the spleen of 8-week-old littermates to determine whether PlGF mRNA is overexpressed in transgenic mice. All transgenic mice showed appropriate insertion into genomic DNA, and PlGF mRNAs were overexpressed in transgenic mice (≥3-fold), whereas PlGF knockout mice did not exhibit PlGF mRNA expression ( Figure 1C ). In addition, when splenocytes were cultured with anti-CD3/CD28 antibody, secretion of PlGF was increased significantly compared with wild-type (WT) mice, whereas the serum PlGF level was unchanged ( Figure 1D ).
Defects of Litter Size and Weight Gain in PlGF Overexpressing Mice
When hetero transgenic males were crossed with WT females, the females occasionally gave birth to dead fetuses on postnatal day 1. Genomic DNA analysis of the dead fetuses revealed that they were transgenic mice (Figure 2A) . Furthermore, analysis of the litter size and birth rate revealed that littermates of PlGF transgenic mice were smaller than WT mice and control transgenic mice that expressed another gene 19 by the human CD-2 promoter ( Figure 2B and 2C) . Interestingly, the birth rate of transgenic mice did not follow Mendelian inheritance. We suggest the possibility that the human CD-2 promoter generates nonaffected in transgenic mice.
Because sizes of littermates were smaller compared with those of the WT, we measured the body weight of littermates every 2 weeks to examine whether PlGF can also affect growth. The body weights of PlGF transgenic mice were considerably lower than those of WT mice, the differences increased gradually ( Figure 2D ). Taken together, these findings indicate that overexpression of PlGF may cause death during gestation and that growth is restricted even after birth. 
PlGF Overexpressing Embryos Show Severe Gestational Loss
To determine whether PlGF overexpression causes defects such as lethality and growth restriction in mice, we examined and compared embryonic WT and transgenic mice. Specifically, we observed the status of fetuses from WT female mice mated with transgenic male mice, from 13.5 embryonic days to 18.5 embryonic days (data not shown), which is the period in which the thymus begins to develop. Although there was no specific day on which embryonic developmental disability began, we identified differences in the developmental phenotype between WT and transgenic mice. However, in early gestation (before E13.5d), transgenic did not have more gestational loss to compare with WT. Therefore, all subsequent experiments were stopped on embryonic day 17.5, at which we observed embryos in pregnant female mice. Transgenic mice had fewer vessels in the yolk sac, embryo body, and placental disk ( Figure 3A) . As a control, we transferred the embryos of knockout mice into recipient mice. This result suggests that gestational loss may have occurred. Furthermore, the gestational loss rate was 34.5% for transgenic mice, whereas it was 10.3% and 10.5% for WT and knockout mice, respectively ( Figure 3B ). These findings confirmed that severe gestational loss occurred in PlGF overexpressing mice, whereas deletion of PlGF in mice had no effect on embryo development ( Figure 3B ). Moreover, although the birth of WT mice to transgenic mice did not follow Mendelian inheritance ( Figure 2B ), the rate in the embryonic stage did ( Figure 3B ).
Histological Analysis of Placental Defects
Because transgenic mice had severe gestational loss and fewer vessels in the fetus, we hypothesized that the placenta is also affected in PlGF overexpressing mice. We performed hematoxylin and eosin and von Willebrand factor staining to examine the placenta of transgenic mice. As we expected, transgenic mice showed reduced vessel formation in the placenta, and we also observed placental detachment from the uterus of the mother ( Figure 4A-4C ). We think that insufficient angiogenesis in transgenic mice causes the detachment of the placenta, resulting in failure to produce littermates, and that insufficient angiogenesis in transgenic mice influences gestational loss of the fetus.
Regulation of Angiogenic Signal in Placenta
Because angiogenesis was severely reduced in the placenta (Figure 4) , we investigated the detailed biological mechanism of this process. We analyzed phosphorylated AKT, endothelial nitric oxide synthase (eNOS), Braf, and ERK in the placenta to identify their activation levels. There were no differences in AKT and eNOS signaling, but Braf and ERK activation differed between WT and transgenic mice. Reduction of phosphorylated ERK and phosphorylated Braf levels was accompanied by a downregulation of HIF-1α levels ( Figure 5A ). HIF-1α is a known downstream target of ERK signaling in placental development 16 and trophoblast differentiation. 20 Real-time polymerase chain reaction revealed that PlGF was expressed in T cells from the placenta of transgenic mice, whereas its expression in T cells from the placentas of WT mice was extremely low. VEGF-A 164 mRNA expression was slightly higher than in WT mice ( Figure 5B ), indicating that overexpression of PlGF is closely related to the antiangiogenesis pathway. At this time, We confirmed the formation of VEGF, PlGF homodimer, and VEGF/PlGF heterodimer through ELISA in transgenic mice placenta. 21 The result showed that there were no significant differences in the formation of heterodimer between WT and transgenic mice. Instead of it, PlGF homodimer formation was significantly induced because increased levels of PlGF homodimerization may cause placenta detachment ( Figure 5C ). We confirmed T-cell phenotype from placenta. The results show that the expressions of mRNAs (interleukin-2, interleukin-10, and Foxp3) that are related with regulatory T-cell development were significantly downregulated. From these data, we now think that subsequent reduction of suppressor T-cell function may cause gestational loss in transgenic mice ( Figure 5D ).
Discussion
In this study, we investigated the relationship between PlGF and angiogenesis using PlGF transgenic mice in which PlGF is expressed in the T cells. The PlGF secretion level was increased in isolated T cells with activated CD3/CD28 from transgenic mice (data not shown) and splenocytes with activated CD3/ CD28 from transgenic mice, whereas there was no difference in PlGF expression in the adult serum between WT and transgenic mice. We determined that the expression level of PlGF in transgenic mice is higher than WT mice only at the first stage of T-cell development. After which there was no specific stimulation of T cells in adult mice. The expression level of PlGF in adult serum after T-cell stimulation needs to be further examined.
The placenta is made by the compounds that are produced by the mother and fetus and attaches anywhere on the wall of the uterus. Placental abruption, which occurs when a normally located placenta is completely or partially separated from the uterine site, can cause stress in the fetus such as oxygen deficiency and nutritional deficiency, which affects the fetus before and after birth. As a result, serious placental abruption can cause the fetus to die or be born with serious problems. [22] [23] [24] Previous studies have shown that PlGF expression in the placenta increased during intrauterine growth restriction 8 and that the growth of tumors and angiogenesis in the tumors decreased when PlGF is overexpressed.
21,25-30
Overexpression of VEGF, which is a typical angiogenic factor, caused defective development of both the extraembryonic tissues and the embryo. 31, 32 Based on these data, we focused on the relationship between PlGF and angiogenesis in the placenta. We found that transgenic mice showed severe angiogenic defects that could cause gestational loss. Even after they are born, transgenic mice show growth retardation compared with WT mice. In addition, insufficient angiogenesis in transgenic mice causes detachment of the placenta, and this insufficient angiogenesis induces gestational loss of the fetus, but there was no difference in the angiogenesis of the umbilical vein between WT and transgenic mice as determined by in vitro angiogenesis assay (data not shown). 33 We found that detachment of the placenta in transgenic mice was a result of placental abruption. Furthermore, we confirmed the decrease of regulatory T cells, which play critical role in maintenance pregnancy. Until now, other studies of gestational loss have focused on the mother; however, our research focused on gestational loss with regard to the fetus. Overall, this study demonstrated that fetal PlGF overexpression in T cells induced gestational loss through the antiangiogenesis pathway, regardless of whether the mother was of the WT. + T cells, which are angiogenic T cells, play important roles in neovascularization. During culture of human peripheral blood mononuclear cells, angiogenic T cells are found at the center of endothelial progenitor cell colonies. Angiogenic T cells exert activity during colony formation and in early endothelial progenitor cells. High levels of angiogenic cytokines such as VEGF and interleukin-8 were secreted by angiogenic T cells. 11, [34] [35] [36] We evaluated the CD31 mRNA levels of adult splenocytes for a 12-hour incubation to determine why transgenic mice showed reduced angiogenesis compared with WT mice. Transgenic mice showed lower levels of CD31 mRNA, which is an angiogenic T-cell marker, whereas PlGF knockout mice showed the highest levels. To confirm the real-time polymerase chain reaction data, we investigated CD3
+ T cells in cultured splenocytes using fluorescence-activated cell sorter and found that transgenic mice have more angiogenic T cells than WT and knockout mice. In addition, we investigated the effects of PlGF on the differentiation of naive CD4 + T cells; however, no differences between WT and transgenic mice were observed (data not shown). These results suggest that PlGF is not associated with angiogenic T cells and differentiation of naive CD4 + T cells. PlGF is closely related to the ERK and AKT signaling pathways, 37 and ERK and HIF-1α signaling are essential factors that must be strictly regulated to achieve normal placental development. 16, 20 The results revealed that overexpression of PlGF reduces the activity of Braf and ERK, but not AKT and eNOS, indicating that PlGF is related to antiangiogenesis. 8, 15, 38 We showed that the reduction of ERK phosphorylation in transgenic mice can sequentially induce angiogenic defects while there are no significant differences in eNOS and AKT phosphorylaytion. We anticipate that eNOS and ERK are activated through different signaling mechanisms. 39 Although the mechanism has not yet been elucidated, our current results suggest that PlGF is important for antiangiogenesis in the placenta and is related to Braf, ERK, and HIF-1α signaling.
There are many causes of miscarriage such as infection, anatomic abnormalities, chromosomal abnormalities, and immune defects. [40] [41] [42] Especially in reproductive immunology, plenty of studies in natural killer cells and regulatory T cells have been accomplished. Regulatory T cells, as an immune suppressor, are known for playing pivotal role in maintenance pregnancy of mouse and human. [43] [44] [45] We found out different phenotype T cell in placenta of overexpressed PlGF mice. Decreased regulatory T cell from transgenic placenta could be possible to induce gestational loss. We suggest that this results may be occurred by increasing inflammation. In conclusion, when PlGF is overexpressed in the fetus, gestational loss and angiogenic defects occur during embryonic development. These findings indicate that although PlGF is required for placental development, excess expression of PlGF can induce antiangiogenesis by inhibiting Braf and ERK activation. Also, transcriptional factor and cytokines related to regulatory T cell were decreased in the placenta of PlGF overexpressed mice. In further study, we will study on exact mechanism about what function PlGF has on inhibition of Braf. Identification of the PlGF mechanism may increase our understanding of fetal development and maintenance of pregnancy.
The present study demonstrates that relationship between fetus and gestational loss. Many studies about gestational loss have concentrated on the mother, but our research focused on gestational loss with regard to the fetus. Placental growth factor is necessary factor for placental development, However, placental growth factor overexpression in fetus induced gestational loss and angiogenesis defects during embryonic development. When placental growth factor is excessively expressed, antiangiogenesis can be induced by inhibiting Braf and extracellular signal-regulated kinase activation. In addition, we showed the decrease of regulatory T cells, which play key role in maintenance pregnancy. Study about placental growth factor mechanism may help understanding of fetal development and maintenance of pregnancy.
Significance

